StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Guggenheim Starts Biogen (BIIB) at Buy
October 23, 2017 4:20 PM
Guggenheim initiates coverage on Biogen (NASDAQ: BIIB) with a Buy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
New Coverage
Next Articles
Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM
BMO Capital Upgrades Biogen (BIIB) to Outperform
October 25, 2017 1:01 AM